418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1828851825583849472 |
|---|---|
| author | Neal Shore Christian Poehlein Charles Schloss Anthony Joshua Evan Yu Johann De Bono Xin Tong Li Gero Kramer |
| author_facet | Neal Shore Christian Poehlein Charles Schloss Anthony Joshua Evan Yu Johann De Bono Xin Tong Li Gero Kramer |
| author_sort | Neal Shore |
| collection | DOAJ |
| first_indexed | 2024-12-12T23:39:31Z |
| format | Article |
| id | doaj.art-fff809a5e1074a7184fceb891f80ede8 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-12T23:39:31Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-fff809a5e1074a7184fceb891f80ede82022-12-22T00:07:15ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.418418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinomaNeal Shore0Christian Poehlein1Charles Schloss2Anthony Joshua3Evan Yu4Johann De Bono5Xin Tong Li6Gero Kramer7Carolina Urologic Research Center, Myrtle Beach, South Carolina, USAAff400 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA6Merck and Co., Inc., Kenilworth, NJ, USA3Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, NSW, AustraliaDepartment of Complex Genetics and Epidemiology, Maastricht University, Maastricht, The Netherlands3The ICR and Royal Marsden, London, UK16Merck and Co., Inc., Kenilworth, NJ, USA3Medical University of Vienna, Vienna, Austria |
| spellingShingle | Neal Shore Christian Poehlein Charles Schloss Anthony Joshua Evan Yu Johann De Bono Xin Tong Li Gero Kramer 418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma Journal for ImmunoTherapy of Cancer |
| title | 418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma |
| title_full | 418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma |
| title_fullStr | 418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma |
| title_full_unstemmed | 418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma |
| title_short | 418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma |
| title_sort | 418 phase 1b 2 keynote 365 cohort i platinum containing chemotherapy alone or in combination with pembrolizumab for treatment emergent neuroendocrine prostate carcinoma |
| work_keys_str_mv | AT nealshore 418phase1b2keynote365cohortiplatinumcontainingchemotherapyaloneorincombinationwithpembrolizumabfortreatmentemergentneuroendocrineprostatecarcinoma AT christianpoehlein 418phase1b2keynote365cohortiplatinumcontainingchemotherapyaloneorincombinationwithpembrolizumabfortreatmentemergentneuroendocrineprostatecarcinoma AT charlesschloss 418phase1b2keynote365cohortiplatinumcontainingchemotherapyaloneorincombinationwithpembrolizumabfortreatmentemergentneuroendocrineprostatecarcinoma AT anthonyjoshua 418phase1b2keynote365cohortiplatinumcontainingchemotherapyaloneorincombinationwithpembrolizumabfortreatmentemergentneuroendocrineprostatecarcinoma AT evanyu 418phase1b2keynote365cohortiplatinumcontainingchemotherapyaloneorincombinationwithpembrolizumabfortreatmentemergentneuroendocrineprostatecarcinoma AT johanndebono 418phase1b2keynote365cohortiplatinumcontainingchemotherapyaloneorincombinationwithpembrolizumabfortreatmentemergentneuroendocrineprostatecarcinoma AT xintongli 418phase1b2keynote365cohortiplatinumcontainingchemotherapyaloneorincombinationwithpembrolizumabfortreatmentemergentneuroendocrineprostatecarcinoma AT gerokramer 418phase1b2keynote365cohortiplatinumcontainingchemotherapyaloneorincombinationwithpembrolizumabfortreatmentemergentneuroendocrineprostatecarcinoma |